Fable Therapeutics

Executive Summary

Fable Therapeutics is a San Diego-based biotechnology company founded in 2020 that leverages machine learning to design enhanced protein therapeutics for metabolic diseases, particularly obesity and related comorbidities. By integrating AI into its drug discovery platform, the company aims to unlock traditionally challenging targets and develop best-in-class biologics. Despite being privately held with no disclosed funding or valuation, Fable Therapeutics operates at the forefront of AI-driven drug development, a field attracting significant interest. The company's focus on metabolic disease addresses a large and growing market, but it faces intense competition from both established players and other AI-native biotechs. As a preclinical-stage company with no publicly disclosed pipeline, its near-term progress remains uncertain, though its AI platform could accelerate discovery timelines if successful.

Upcoming Catalysts (preview)

• 2026Series A or Seed Funding Announcement50% success
• 2026Nomination of Lead Preclinical Candidate40% success
• 2026Presentation of Preclinical Data at Major Conference30% success